Position in PTGX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,120,764
+$734,719 QoQ
Shares Held
25,459
+12.5% QoQ
Ownership
0.039%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#122
of 341 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026NATIXIS ADVISORS, LLC holds $495,549,179 across 38 Biotechnology names. PTGX ranks #19 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
448,631 | $222,848,476 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
129,236 | $80,583,815 | |
| 3 | TECH |
BIO-TECHNE Corp
|
818,905 | $57,855,638 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
75,311 | $22,670,870 | |
| 5 | ARGX |
Argenx SE
|
19,088 | $17,709,273 | |
| 6 | INSM |
INSMED Inc
|
73,607 | $7,847,978 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
97,536 | $7,634,142 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
29,928 | $7,211,749 |
All Filings in PTGX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,120,764 | 25,459 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $2,386,045 | 22,638 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $1,790,033 | 20,495 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $1,119,677 | 16,855 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $742,939 | 13,442 | Shares | Defined | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||